May 05, 2026

Prescribing Outside the Exam Room

A DEA case exposes how controlled substances can move outside clinical oversight.

Conexiant

May 04, 2026

FDA Expands ASCENIV Pediatric Use

Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility.

Conexiant

May 04, 2026

Food Fight Brewing in Hospitals

New federal diet push collides with clinical realities, as doctors weigh patient needs against policy signals.

KFF Health News

April 30, 2026

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

Conexiant

April 30, 2026

Urgent Care, Unchecked Power

An unsupervised clinic model and blurred boundaries expose how oversight can fail in outpatient care.

Conexiant

April 29, 2026

FDA Reports Results of Nationwide Infant Formula Testing

Federal testing survey examines chemical contaminant profiles across widely used products

Conexiant

April 29, 2026

FDA Updates Lumateperone Label With Relapse-Prevention Data

Label update incorporates randomized withdrawal trial findings showing delayed time to relapse and consistent safety profile in schizophrenia

Conexiant

April 29, 2026

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

April 28, 2026

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

Conexiant

April 28, 2026

FDA Clears Breztri for Asthma Use

Single-inhaler triple therapy improved lung function vs dual therapy in phase 3 trials and showed rapid onset without new safety signals.

Conexiant